Mutation in **CDKN1B** 3’-UTR region in a patient with acromegaly and primary hyperparathyroidism

E. Mamedova, N. Mokrysheva, E. Pigarova, E. Przhiyalkovskaya, E. Vasiliev, L. Rozhinskaya, A. Tiulpakov

*Endocrinology Research Centre, Moscow, Russian Federation*

**Introduction.** Multiple endocrine neoplasia type 4 (MEN4) is a rare disorder, caused by inactivating mutations in **CDKN1B** gene that encodes p27^{kip1} cyclin-dependent kinase inhibitor. To date several different germline **CDKN1B** mutations have been described in patients with clinical features of multiple endocrine neoplasia type 1 (MEN1) negative for **MEN1** mutations (MEN1 phenocopies).

**Case report.** A female 54 y.o. with clinical features of MEN1, apparently sporadic, negative for **MEN1** germline mutation.

**Acromegaly**
- Manifestation at 46 y.o.
- Macroadenoma (endo-para(S)-infrasellar)
- Residual tissue in left cavernous sinus
  After transcranial and transnasal operations

**Primary hyperparathyroidism**
- Detection at 54 y.o.
- Superior right parathyroid adenoma
- Mild PHPT (serum total Ca - 2.79 mmol/l, iCa - 1.3 mmol/l, PTH - 79 pg/ml

**Other lesions**
- Extirpation of uterus and ovaries for adenomatous endometrial polyp, multinodular fibromyoma and endometrioid cyst
- Right mammary gland resection for benign lesion

**Genetic testing.** High-throughput sequencing on the Ion Torrent Personal Genome Machine (Life Technologies, USA) using a custom-designed AmpliSeq™ panel revealed a heterozygous mutation in 3’-UTR g.3897G>T (c*8G>T) in **CDKN1B** gene. *In silico* testing predicted splice site alterations. Further *in vitro* studies are needed to confirm whether this mutation alters protein function.

**Conclusions.** To our knowledge, we describe the first mutation in 3’-UTR of **CDKN1B** in a patient with MEN1 phenocopy.

**Funding.** This work was supported by the Grant of the President of the Russian Federation for young PhD scientists “Molecular genetic basis of familial pituitary adenomas” (MK-5411.2014.7).